|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLX4IP |
Gene summary for SLX4IP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLX4IP | Gene ID | 128710 |
| Gene name | SLX4 interacting protein | |
| Gene Alias | C20orf94 | |
| Cytomap | 20p12.2 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q5VYV7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 128710 | SLX4IP | CCI_2 | Human | Cervix | CC | 6.81e-10 | 8.06e-01 | 0.5249 |
| 128710 | SLX4IP | CCI_3 | Human | Cervix | CC | 2.87e-05 | 5.84e-01 | 0.516 |
| 128710 | SLX4IP | LZE4T | Human | Esophagus | ESCC | 2.61e-08 | 2.84e-01 | 0.0811 |
| 128710 | SLX4IP | LZE7T | Human | Esophagus | ESCC | 1.28e-02 | 2.26e-01 | 0.0667 |
| 128710 | SLX4IP | LZE24T | Human | Esophagus | ESCC | 7.59e-05 | 1.59e-01 | 0.0596 |
| 128710 | SLX4IP | P2T-E | Human | Esophagus | ESCC | 2.65e-20 | 2.60e-01 | 0.1177 |
| 128710 | SLX4IP | P4T-E | Human | Esophagus | ESCC | 1.13e-10 | 2.74e-01 | 0.1323 |
| 128710 | SLX4IP | P5T-E | Human | Esophagus | ESCC | 1.74e-16 | 1.60e-01 | 0.1327 |
| 128710 | SLX4IP | P8T-E | Human | Esophagus | ESCC | 8.97e-18 | 1.21e-01 | 0.0889 |
| 128710 | SLX4IP | P9T-E | Human | Esophagus | ESCC | 1.93e-02 | 1.30e-01 | 0.1131 |
| 128710 | SLX4IP | P10T-E | Human | Esophagus | ESCC | 2.96e-20 | 2.88e-01 | 0.116 |
| 128710 | SLX4IP | P11T-E | Human | Esophagus | ESCC | 1.89e-06 | 2.61e-01 | 0.1426 |
| 128710 | SLX4IP | P12T-E | Human | Esophagus | ESCC | 1.21e-12 | 2.58e-01 | 0.1122 |
| 128710 | SLX4IP | P15T-E | Human | Esophagus | ESCC | 2.72e-10 | 2.53e-01 | 0.1149 |
| 128710 | SLX4IP | P16T-E | Human | Esophagus | ESCC | 2.58e-29 | 3.31e-01 | 0.1153 |
| 128710 | SLX4IP | P17T-E | Human | Esophagus | ESCC | 2.50e-04 | 2.64e-01 | 0.1278 |
| 128710 | SLX4IP | P20T-E | Human | Esophagus | ESCC | 1.53e-13 | 3.03e-01 | 0.1124 |
| 128710 | SLX4IP | P21T-E | Human | Esophagus | ESCC | 7.82e-16 | 2.23e-01 | 0.1617 |
| 128710 | SLX4IP | P22T-E | Human | Esophagus | ESCC | 2.95e-11 | 1.27e-01 | 0.1236 |
| 128710 | SLX4IP | P23T-E | Human | Esophagus | ESCC | 6.07e-17 | 3.89e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLX4IP | insertion | In_Frame_Ins | novel | c.944_945insCCTTAACAT | p.Ser315_Asp316insLeuAsnIle | p.S315_D316insLNI | Q5VYV7 | protein_coding | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| SLX4IP | insertion | Frame_Shift_Ins | novel | c.946_947insGAAATGAATACCTATTTACCTT | p.Asp316GlyfsTer48 | p.D316Gfs*48 | Q5VYV7 | protein_coding | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| SLX4IP | insertion | Nonsense_Mutation | novel | c.1002_1003insAATACCTATTTACCTTAGTTAAAATGTGAACGCCATCATAAAT | p.Pro335AsnfsTer6 | p.P335Nfs*6 | Q5VYV7 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| SLX4IP | insertion | Nonsense_Mutation | novel | c.778_779insTCTGCATTTAAACATACACCT | p.Gly260delinsValCysIleTerThrTyrThrTrp | p.G260delinsVCI*TYTW | Q5VYV7 | protein_coding | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | ||
| SLX4IP | insertion | In_Frame_Ins | novel | c.1076_1077insAACTAA | p.Leu359_His360insThrLys | p.L359_H360insTK | Q5VYV7 | protein_coding | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR | ||
| SLX4IP | insertion | In_Frame_Ins | novel | c.1077_1078insTCCTACTCCCATTTGTTGATCAAGTTTGGTCAA | p.Leu359_His360insSerTyrSerHisLeuLeuIleLysPheGlyGln | p.L359_H360insSYSHLLIKFGQ | Q5VYV7 | protein_coding | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR | ||
| SLX4IP | deletion | Frame_Shift_Del | novel | c.273delN | p.Arg92GlufsTer37 | p.R92Efs*37 | Q5VYV7 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SLX4IP | SNV | Missense_Mutation | novel | c.670N>C | p.Asp224His | p.D224H | Q5VYV7 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-AA-3695-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SLX4IP | SNV | Missense_Mutation | novel | c.575N>A | p.Thr192Lys | p.T192K | Q5VYV7 | protein_coding | tolerated(0.41) | benign(0.012) | TCGA-AA-3930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
| SLX4IP | SNV | Missense_Mutation | c.628N>A | p.Ala210Thr | p.A210T | Q5VYV7 | protein_coding | tolerated(0.77) | benign(0.104) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |